BFM
REGN icon

Boothbay Fund Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Boothbay Fund Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-98
Closed -$4.79M – 1087
2020
Q1 		$4.79M Buy
+98
New +$40.4K 0.4% 52
2018
Q3 		– Sell
-476
Closed -$16.4M – 922
2018
Q2 		$16.4M Buy
+476
New +$149K 1.43% 12

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Boothbay Fund Management's REGN Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 2,972 shares worth $2.3M. The stake represents 0.03% of the portfolio and ranks #560 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in REGN as recently as Q3 2025.

Boothbay Fund Management first reported a position in REGN in Q2 2019 and has held it in 14 quarters since. The position peaked at $8.82M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Boothbay Fund Management held 2,972 shares of Regeneron Pharmaceuticals worth $2.3M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Boothbay Fund Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #560 holding.
  • Boothbay Fund Management first reported a position in Regeneron Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
  • Boothbay Fund Management's Regeneron Pharmaceuticals position peaked at $8.82M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.